Kite Pharma (NASDAQ:KITE) target upped to $65.00, released a research note earlier today by Barclays Capital
- Updated: September 27, 2016
Boasting a price of $59.72, Kite Pharma (NASDAQ:KITE) traded 8.79% higher on the day. With the last stock price up 16.03% from the two hundred day average, compared with the Standard & Poor's 500 Index which has decreased -0.01% over the same period. KITE has recorded a 50-day average of $58.24 and a two hundred day average of $51.55. Volume of trade was up over the average, with 4,321,835 shares of KITE changing hands over the typical 822,277
Barclays Capital upped the price target of Kite Pharma (NASDAQ:KITE) to $65.00 stating a potential upside of 0.09%.
Previously on 9/13/2016, Vetr Inc. reported on Kite Pharma (NASDAQ:KITE) increased the target price from $0.00 to $63.91. At the time, this suggested an upside of 0.12%.
Kite Pharma has 52 week low of $38.41 and a 52 week high of $89.84 and has a market cap of $0.
In addition to Barclays Capital reporting its stock price target, a total of 11 brokerages have issued a ratings update on the company. The average target price is $74.18 with six analysts rating the company a strong buy, seven equity analysts rating the company a buy, zero brokerages rating the company a hold, zero analysts rating the stock a underperform, and finally 0 equity analysts rating the company a sell.
Brief Synopsis About Kite Pharma (NASDAQ:KITE)
Kite Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products to eradicate cancer cells. The Company offers engineered autologous cell therapy (eACT), which is an approach to the treatment of cancer. It is conducting over four pivotal studies of its lead product candidate, KTE-C19, a CAR-based therapy. It is conducting a Phase II clinical trial (ZUMA-1) of KTE-C19 in patients with refractory diffuse large B cell lymphoma (DLBCL), including primary mediastinal B cell lymphoma (PMBCL) and transformed follicular lymphoma (TFL). It is also conducting a Phase II clinical trial (ZUMA-2) of KTE-C19 in patients with relapsed/refractory mantle cell lymphoma (MCL), a Phase I-II clinical trial (ZUMA-3) of KTE-C19 in adult patients with relapsed/refractory acute lymphoblastic leukemia (ALL), and a Phase I-II clinical trial (ZUMA-4) of KTE-C19 in pediatric patients with relapsed/refractory ALL.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.